Laurus Labs Ltd

- The transcript does not mention any specific plans for new fundraising through debt or equity in the near term. - Current net debt stands at Rs. 2,633 crores, with a target to reduce the net debt to EBITDA ratio to less than 2.5 by March 2025. - CAPEX of around Rs. 1800 to Rs. 2000 crores is planned over the next two years, primarily funded by advances from customers for specific CMO capacity expansions and internal resources. - The company is prioritizing investments into high-value business segments and improving working capital efficiency without indicating the need for immediate external funding. - No explicit mention of fresh equity issuance or debt raising during this period was found in the transcript.

- Capex planned for FY24 and FY25 is around Rs. 1800 to Rs. 2000 crores, mainly directed toward CDMO and finished dosage formulations (FDF) expansion. - Additional FDF capacity expansion at Unit-2 in Vizag: increasing from 10 billion to 13 billion tablets over 18 months, driven by specific customer CMO contracts, mostly for generic products; majority of this CAPEX will be funded by customer advances. - Rs. 200 crore investment planned into fermentation facility at Vizag, expected to be commissioned by mid-2026, focusing on GMP pharmaceutical manufacturing. - Ongoing investment in new R&D center at Genome Valley to support expanded CDMO capabilities. - Total historic CAPEX of Rs. 2600 crore of which around 75% is for CDMO projects, currently underutilized due to phased project execution. - Long-term investments include Animal Health and Crop Protection Ingredients facilities, with Crop Protection qualification targeted by end FY25.

- Q1 FY25 revenue was flattish at Rs. 1,195 crores, expected to pick up in H2 FY25 due to clinical phase project deliveries. - Oncology APIs growing strongly, with Q1 sales up 120% YoY; new oncology products validated, awaiting regulatory approvals. - ARV franchise expected to remain stable at around Rs. 2,400-2,500 crores annually. - CDMO business anticipates healthy growth supported by late-stage NCE project deliveries scheduled in Q4 FY25. - Commercial supplies from about 10 products ongoing; new registrations and late-stage projects indicate commercial volumes likely from FY26. - Expansion plans (formulations, fermentation facility at Vizag, animal health, crop protection) targeting medium to long-term growth. - Pipeline includes 62 products under review/development with significant addressable market value. - CMO collaborations and expanded oral solid dosage manufacturing lines expected to contribute to future revenue growth.

- FY25 expected to be a good year with better performance in H2; Q1 aligns with internal guidance (Page 10). - FY26 anticipated to be a much better year, driven by assets like Animal Health starting to yield results (Page 10). - EBITDA margins expected to improve in H2 FY25 from current subdued levels due to lower asset utilization and investments (Page 6). - Gross margins maintained around 50% for 8 quarters with confidence to sustain despite pricing pressures (Page 14). - CDMO business expected to grow with scheduled deliveries of clinical phase projects primarily in Q4 FY25, contributing to revenues beyond base Rs. 200 crores per quarter (Pages 10, 14). - Continued investments of Rs. 1800-2000 crores planned over next 2 years, focusing on CDMO and FDF expansions (Page 14). - Diluted EPS for Q1 FY25 at Rs. 0.23 with anticipated growth thereafter (Page 6).

- The current order book for Laurus Labs' product basket looks encouraging, supported by additional supply contracts secured through successful tenders. - The company is working on over 70 active CDMO projects. - They have on-hand orders for clinical phase project deliveries expected mostly in H2 FY25. - CDMO commercial deliveries base is about Rs. 200 crores per quarter, excluding new order opportunities. - New CDMO commercial orders are expected to start contributing significantly from FY26 onwards. - For ARVs, about $100 million sales occur with 25% formulation capacity utilization. - Some key late-phase NCE projects have scheduled deliveries expected in Q4 FY25. - Expansion plans include additional CMO contracts which will add capacity and are backed by confirmed volumes and pricing, ensuring business stability. - Joint venture with KRKA and new customer partnerships support order visibility and capacity utilization growth.